Clinical Trial

Lung Cancer Organoids and Patient Derived Tumor Xenografts

Study acronym: IPON-3
Active, Not Recruiting
View on ClinicalTrials.gov →
Summary
Extra tissue will be taken from patient during a procedure in standard of care. Also, through an existing line, 10ml of extra blood will be drawn. From this material the investigator will try to establish matched normal and primary human lung cancer organoids.
Protocol Amendment History 7 amendments
This ClinicalTrials.gov record has been amended 7 times since 2021-10-11; most recent amendment 2026-07-09.
Status change: Recruiting → Active, Not Recruiting 2026-07-09
Status change: Not Yet Recruiting → Recruiting 2022-08-23
Trial Details
NCT Number NCT05092009
Lead Sponsor Maastricht Radiation Oncology
Conditions Lung Cancer
Enrollment 600 participants
Start Date 2022-10-05
Primary Completion 2026-10-01 (estimated)
Study Completion 2028-04-01 (estimated)
Updated on ClinicalTrials.gov 2026-07-13